Posts by Katy Lees
Why 340B Matters: A Response to PhRMA’s Middleman Narrative
This blog offers a clear, evidence-based response to that narrative by outlining what the 340B program actually does, who it serves, and why it remains indispensable for underserved patients and the safety-net providers who care for them.
Read MorePlanning for Change: The Intersection of IRA Maximum Fair Price and the 340B Rebate Policies
The IRA’s Maximum Fair Price and HRSA’s 340B rebate pilot are set to reshape drug reimbursement in 2026. Learn how covered entities can prepare, prevent duplication, and stay compliant.
Read More340B Rebate Pilot: Why Purchase Data Isn’t the Right Tool for Duplicate Discount Prevention
As the 340B rebate pilot approaches its January 2026 launch, some argue that requiring purchase data will prevent duplicate discounts. But in practice, this approach introduces complexity, misaligned timing, and inconsistent reporting. Transactional claim data remains the most accurate and reliable method for identifying duplicate discounts, ensuring compliance, and maintaining program integrity — without undermining the pilot’s core goals.
Read MoreReflections from the 2025 MDRP Summit
At the 2025 MDRP Summit, one theme was clear: collaboration between manufacturers, states, and covered entities is essential, but today’s systems often inflate disputes and obscure the true value of 340B. Katy reflects on why better communication, accurate data, and good-faith engagement are critical to protecting patient care.
Read More